Limosilactobacillus reuteri CCFM1132 Modulates Gut Microbiota and Alleviates Hyperuricemia: A Randomized, Double-Blind, Placebo-Controlled Trial

Lei Sun^{¹^,²}, Yang Cao^³, Feng Hang^{¹^,²^,⁴^,⁵}, Dongbo Yuan^⁶, Honglun Wang^⁷, Jianxin Zhao^{¹^,²^,⁴^,⁵}, Gang Wang^{¹^,²^,⁴^,⁵}(), Guohong Qiao^⁶(), Liyun Wang^⁸()

¹State Key Laboratory of Food Science and Resources, Jiangnan University, Wuxi, Jiangsu 214122, China.

²School of Food Science and Technology, Jiangnan University, Wuxi, Jiangsu 214122, China.

³Department of Biostatistics, Harvard T.H. Chan School of Public Health

⁴National Engineering Research Center for Functional Food, Jiangnan University, Wuxi, Jiangsu 214122, China.

⁵(Yangzhou) Institute of Food Biotechnology, Jiangnan University, Yangzhou 225004, China

⁶Department of Clinical Laboratory, Yixing People’s Hospital, Affiliated to Jiangsu University, Yixing 214200, China

⁷Qinghai Provincial Key Laboratory of Tibetan Medicine Research, 810008, Xining, P. R. China

⁸Department of Endocrine Metabolism, Yixing People’s Hospital, Affiliated to Jiangsu University, Yixing 214200, China

Show Author Information

Abstract

This randomized, double-blind, placebo-controlled trial evaluated the uric acid (UA)-lowering effect of Limosilactobacillus reuteriCCFM1132 in young males with hyperuricemia. Participants received 1×10¹⁰ CFU of L. reuteri CCFM1132 (n=34) or placebo (n=31) daily for 8 weeks. After the intervention, serum UA concentration significantly decreased, along with a reduction in xanthine oxidase (XOD) activity compared to the placebo group (P < 0.01). Indicators of liver (aspartate transaminase and alanine transaminase) and renal (urea and creatinine) functions improved. Short-chain fatty acid (SCFA) concentrations significantly increased, with an upregulated abundance of SCFA producers (Fusicatenibacter, Ruminococcaceae UCG_014, and Ruminococcus 1) in the gut. Additionally, correlation analysis revealed that concentrations of SCFAs, particularly acetate and butyrate, were strongly negatively correlated with UA concentration and XOD activity. These findings suggest that L. reuteri CCFM1132 relieves hyperuricemia by enhancing the abundance of SCFA producers in the gut to promote SCFA production and by suppressing XOD activity. This study provides a valuable reference for developing new treatments for hyperuricemia

Keywords

Hyperuricemia Limosilactobacillus reuteri Xanthine oxidase Short-chain fatty acid Gut microbiota

Electronic Supplementary Material

Download File(s)

2024-00673R1_ESM.docx (218 KB)

Food Science and Human Wellness

DOI: 10.26599/FSHW.2024.9250316

Cite this article:

Sun L, Cao Y, Hang F, et al. Limosilactobacillus reuteri CCFM1132 Modulates Gut Microbiota and Alleviates Hyperuricemia: A Randomized, Double-Blind, Placebo-Controlled Trial. Food Science and Human Wellness, 2024, https://doi.org/10.26599/FSHW.2024.9250316